Anti-HLA alloantibodies in pediatric solid organ transplantation
Alin L. Girnita,
Steven A. Webber,
Adriana Zeevi,
Alin L. Girnita
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorSteven A. Webber
Division of Cardiology, Children's Hospital, Pittsburgh, PA, USA
Search for more papers by this authorAdriana Zeevi
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorAlin L. Girnita,
Steven A. Webber,
Adriana Zeevi,
Alin L. Girnita
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorSteven A. Webber
Division of Cardiology, Children's Hospital, Pittsburgh, PA, USA
Search for more papers by this authorAdriana Zeevi
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorAdriana Zeevi, 200 Lothrop St, W1551, BST, Pittsburg, PA 15261, USA
Tel.: +1 412 624 1073
Fax: +1 412 647 7741
E-mail: [email protected]
Abstract
Abstract: An increasing number of studies demonstrate the clinical impact of preformed and de novo anti-human leucocyte antigen alloantibody (HLA-Ab) in solid organ transplantation (Tx). The screening of HLA-Ab in candidates and transplant recipients has evolved over time, with continuous improvement in the sensitivity and specificity of assays for HLA-Ab detection. Furthermore, histologic markers of complement activation pathways are currently implemented in the diagnosis of antibody-mediated rejection (AMR). Therapeutic strategies, including depletion of HLA-Ab and B cells, have allowed Tx across antibody barriers, or have rescued patients with AMR. The purpose of the present review is to summarize the state-of-the-art of HLA-Ab detection, clinical significance and therapeutic strategies in pediatric solid organ Tx.
References
- 1 Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969: 280: 735–739.
- 2 Di Filippo S, Girnita A, Webber SA, et al. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol 2005: 66: 513–518.
- 3 Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004: 23: 1135–1141.
- 4 Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005: 5: 131–138.
- 5 McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000: 69: 319–326.
- 6 Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003: 3: 665–673.
- 7 Davenport A, Younie ME, Parsons JE, Klouda PT. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 1994: 9: 1315–1319.
- 8 Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004: 29: 41–54.
- 9 Dalla Vecchia LK, Book BK, Milgrom ML, et al. Predictive value of enzyme-linked immunosorbent assay-detected IgG anti-HLA antibodies for pediatric renal allograft rejection. Transplantation 1997: 64: 1744–1747.
- 10 Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004: 4: 1562–1566.
- 11 Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the joint UNOS/ISHLT thoracic registry. Transplantation 2001: 72: 1662–1665.
- 12 Gjertson DW, Dabrowska DM, Cui X, Cecka JM. Four causes of cadaveric kidney transplant failure: A competing risk analysis. Am J Transplant 2002: 2: 84–93.
- 13 Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998: 98: 786–793.
- 14 Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999: 1: 334–342.
- 15 McKenna RM, Takemoto SK. Improving HLA matching for kidney transplantation by use of CREGs. Lancet 2000: 355: 1842–1843.
- 16 El-Awar N, Terasaki P, Lazda V, Nikaein A, Arnold A. Most patients who reject a kidney transplant have anti-HLA-antibodies. Tissue Antigens 2002: 60: 553.
- 17 Girnita A, Duquesnoy R, Demetris A, et al. De novo anti-HLA antibodies have the highest incidence in the first year after transplantation. Hum Immunol 2003: 64: S77.
- 18 Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758–760.
- 19 Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631–636.
- 20 Al-Uzri AY, Seltz B, Yorgin PD, Spier CM, Andreoni K. Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient. Pediatr Transplant 2002: 6: 161–165.
- 21 Worthington JE, Thomas AA, Dyer PA, Martin S. Detection of HLA-specific antibodies by PRA-STAT and their association with transplant outcome. Transplantation 1998: 65: 121–125.
- 22 Duquesnoy RJ, Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 2002: 63: 353–363.
- 23 Nelson K, Marks W, Warner P, Thompson C, Davis C. Acute humoral rejection is associated with antibodies to HLA-DP. Am J Transplant 2005: 5: 72–73.
- 24 Hoekstra F, Witvliet M, Knoop C, et al. Donor-specific anti-human leukocyte antigen class I antibodies after implantation of cardiac valve allografts. J Heart Lung Transplant 1997: 16: 570–572.
- 25 Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999: 67: 1155–1161.
- 26 Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002: 74: 799–804.
- 27 Susal C, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004: 36: 29–34.
- 28 Gammie JS, Pham SM, Colson YL, et al. Influence of panel-reactive antibody on survival and rejection after lung transplantation. J Heart Lung Transplant 1997: 16: 408–415.
- 29 Adeyi OA, Girnita AL, Howe J, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005: 14: 53–62.
- 30 Hosenpud JD, Mauck KA, Hogan KB. Cardiac allograft vasculopathy: IgM antibody responses to donor-specific vascular endothelium. Transplantation 1997: 63: 1602–1606.
- 31 McCalmon RT Jr, Tardif GN, Sheehan MA, Fitting K, Kortz W, Kam I. IgM antibodies in renal transplantation. Clin Transplant 1997: 11: 558–564.
- 32 Doran TJ, Susal C, Opelz G, Geczy AF. IgA class antibodies and flow cytometric cross-matching in renal transplantation. Transplantation 1999: 67: 309–314.
- 33 Fine RN, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Korsch BM. Renal retransplantation in children. J Pediatr 1979: 95: 244–248.
- 34 D'Apice AJ, Sheil AG, Tait BD, Bashir HV. A prospective randomized trial of matching for HLA-A and B versus HLA-DR in renal transplantation. Transplantation 1984: 38: 37–41.
- 35 Broyer M, Gagnadoux MF, Guest G, Busson M, Beurton D. Results of 310 cadaver kidney transplants in children and adolescents. Arch Fr Pediatr 1985: 42: 237–243.
- 36 Dyer PA, Martin S, Mallick NP, Gokal R, Johnson RW. Kidney transplantation in the northwest region of England – experience of 1,132 transplants in 21 years. Clin Transpl 1989: 201–213.
- 37 Delmonico FL, Tolkoff-Rubin N, Auchincloss H Jr, et al. Second renal transplantations. Ethical issues clarified by outcome; outcome enhanced by a reliable crossmatch. Arch Surg 1994: 129: 354–360.
- 38 Emonds MP, Herman J, Dendievel J, Waer M, Van Damme-Lombaerts R. Evaluation of anti-human leukocyte antigen allo-immunization in pediatric cadaveric kidney transplantation. Pediatr Transplant 2000: 4: 6–11.
- 39 Piatosa B, Grenda R, Rubik J, Prokurat S. The significance of anti-HLA antibody presence in children who lost the transplanted kidney due to vascular thrombosis. Transplant Proc 2002: 34: 589–590.
- 40 Breinholt JP III, Hawkins JA, Lambert LM, Fuller TC, Profaizer T, Shaddy RE. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation 2000: 102: III179–III182.
- 41 Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000: 119: 324–330.
- 42 Hawkins JA, Hillman ND, Lambert LM, et al. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg 2003: 126: 247–252 (discussion 252–243).
- 43 Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996: 94: 1063–1067.
- 44 Dignan R, O'Brien M, Hogan P, et al. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens. J Heart Valve Dis 2003: 12: 382–390 (discussion 390–381).
- 45 Welters MJ, Oei FB, Witvliet MD, et al. A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts. Hum Immunol 2002: 63: 1019–1025.
- 46 Baskett RJ, Nanton MA, Warren AE, Ross DB. Human leukocyte antigen-DR and ABO mismatch are associated with accelerated homograft valve failure in children: implications for therapeutic interventions. J Thorac Cardiovasc Surg 2003: 126: 232–239.
- 47 Smith JD, Hornick PI, Rasmi N, Rose ML, Yacoub MH. Effect of HLA mismatching and antibody status on ‘‘homovital’’ aortic valve homograft performance. Ann Thorac Surg 1998: 66: S212–S215.
- 48 DeNofrio D, Rho R, Morales FJ, et al. Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation. Transplantation 2000: 69: 814–818.
- 49 Bishay ES, Cook DJ, Starling RC, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. Eur J Cardiothorac Surg 2000: 17: 362–369.
- 50 George JF, Kirklin JK, Shroyer TW, et al. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. J Heart Lung Transplant 1995: 14: 856–864.
- 51 Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol 2004: 13: 63–71.
- 52 Tambur AR, Bray RA, Takemoto SK, et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000: 70: 1055–1059.
- 53 Suciu-Foca N, Reed E, Marboe C, et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991: 51: 716–724.
- 54 Reed E, Cohen DJ, Barr ML, et al. Effect of anti-HLA and anti-idiotypic antibodies on the long-term survival of heart and kidney allografts. Transplant Proc 1992: 24: 2494–2495.
- 55 Itescu S, Tung TC, Burke EM, et al. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 1998: 352: 263–270.
- 56 Donaldson PT, Alexander GJ, O'Grady J, et al. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1987: 1: 945–951.
- 57 Lobo PI, Spencer C, Douglas MT, Stevenson WC, Pruett TL. The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation 1993: 55: 1063–1066.
- 58 Karuppan S, Ericzon BG, Moller E. Relevance of a positive crossmatch in liver transplantation. Transpl Int 1991: 4: 18–25.
- 59 Katz SM, Kimball PM, Ozaki C, et al. Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Transplantation 1994: 57: 616–620.
- 60 Saidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994: 2: 61–67.
- 61 Mazariegos GZA, Reyes J, Chapman H, Girnita A, Zeevi A. Immunologic assays in patients successfully withdrawn from immunosuppression after liver transplantation. Am J Transplant 2004: 4: 301.
- 62 Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993: 43: 1333–1338.
- 63 Mengel M, Bogers J, Bosmans JL, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005: 5: 1050–1056.
- 64 Baldwin WM III, Samaniego-Picota M, Kasper EK, et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999: 68: 894–900.
- 65 Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999: 18: 904–912.
- 66 Ionescu DN, Girnita AL, Zeevi A, et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol 2005 (in press).
- 67 Miller GG, Destarac L, Zeevi A, et al. Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant 2004: 4: 1323–1330.
- 68 Bohmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001: 12: 2482–2489.
- 69 Furth S, Neu AM, Hart J, Zachary A, Colombani P, Fivush BA. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Pediatr Transplant 1999: 3: 146–149.
- 70 Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. Pediatr Transplant 2005: 9: 155–161.
- 71 Bunchman TE, Parekh RS, Kershaw DB, et al. Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clin Transplant 1997: 11: 604–607.
- 72 Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887–895.
- 73 Schweizer RT, Bow L, Roper L, Hull D, Bartus SA. Renal transplantation at Hartford hospital: results of combined and flexible immunosuppression. Clin Transpl 1988: 147–158.
- 74 Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003: 25: 119–140.
Citing Literature
